Form 4 for EBS Emergent BioSolutions Inc.

Accepted 2022-12-13 00:00:00 ET · period of report 2022-12-09 · accession 0001367644-22-000156 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
M	2022-12-13	2022-12-09	EBS	Glessner Coleen	EVP, Quality, Ethics, CPL	A - Grant	$0.00	+96.3K	35.9K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2022-12-09	A	A	72,232	$0.00	108,136	D	—	—	(F2) Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in one annual installment beginning on the day prior to the second anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.
2	Common	Common Stock	2022-12-09	A	A	24,078	$0.00	35,904	D	—	—	(F1) Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2022 and ending December 31, 2024, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%.